Blog

Ditch the Mouse: How to Tackle Your Ascites Problem

Despite decades of advancements in in vitro antibody production methods, many of the world’s largest diagnostics and reagents companies are still manufacturing in mice. The ascites method of manufacturing is inherently problematic due to batch inconsistency, supply chain unreliability, quality issues, and the ethics of using animals when alternatives are available.

In this post, we’ll walk through the history of ascites manufacturing, why more and more companies are moving away from ascites, and how it can be effectively accomplished while minimizing risk to the product.

Continue reading “Ditch the Mouse: How to Tackle Your Ascites Problem”

The Perfusion Revolution

Article contributed by Brittni Peterson, PhD, and Emily Wozniak, PhD
Adopting new technologies is a challenge in heavily regulated environments, as innovation is often stymied in favor of safer, established technologies. This is especially true of the biomanufacturing industry. Mainstream bioreactors have been improved only incrementally since the original fermenters that produced ingredients like citric acid in the 1920s (Pictured, left) or yeast in the 1930s and 40s (de Becze and Leibmann, 1944).
Continue reading “The Perfusion Revolution”

Finding your fit: Small-scale CDMOs

Article Contributed by Brittni Peterson, PhD and Emily Wozniak, PhD

Large-scale therapeutic products (many kg’s per year) command respect from contract manufacturers. These products generally consume dedicated manufacturing suites for multiple years and guarantee premium budgets. Their owners are often large pharmaceutical companies with significant resources and a track record of paying for the best.

Most Contract Development and Manufacturing Organizations (CDMOs) cater to these products because they are manufactured at a high price tag and come with guaranteed capacity utilization.

Continue reading “Finding your fit: Small-scale CDMOs”